Tafasitamab-Based Combination Boosts PFS in Relapsed/Refractory Follicular Lymphoma

Published Date: 13 Dec 2024

Benefit seen in all prespecified subgroups, including high-risk patients

Read Full News

Todays Updates


Europe Must Rethink Medicine Pricing or Risk Losing Investment


Europe will need to rethink how it values and pays for innovative ⁠medicines or risk losing manufacturing investments and clinical trials, the head of Europe's pharmaceutical industry lobby said.

Medicare AI Creates Errors and Delays for Patients, Doctors


Patients, doctors, and other healthcare professionals who spoke with KFF Health News say the effort has created confusion, errors, long wait times, and stress.

Is Creatine for Brain Health Worth a Try?


Research on creatine supplementation has moved from the gym to the brain lab, leading neurologist Heidi Moawad to review the data on creatine’s potential for improving cognitive health.

S1 Episode 2: Is Alcohol the Missing Piece in Your MASLD Workup?


Patients with MASLD often underreport alcohol use and even modest intake can block improvement. Drs VanWagner and Ajmera share practical tools to quantify intake, spot MetALD, and counsel patients effectively.

S1 Episode 1: Can Primary Care Catch MASLD Before Cirrhosis?


MASLD is a silent condition and labs may look normal. Drs VanWagner and Shubrook walk through who to screen, how to use FIB-4, and when primary care can manage MASLD without a specialist.

Palbociclib Gains HER2+ Breast Cancer Maintenance Indication


Palbociclib is now the first CDK4/6 inhibitor approved for metastatic disease regardless of HER2 status.

Mirvetuximab Fails to Boost Survival in Platinum-Eligible OC


Mirvetuximab has come up short in the first randomized trial testing an antibody-drug conjugate plus standard carboplatin for patients with platinum-sensitive ovarian cancer.

Todays Updates


Europe Must Rethink Medicine Pricing or Risk Losing Investment


Europe will need to rethink how it values and pays for innovative ⁠medicines or risk losing manufacturing investments and clinical trials, the head of Europe's pharmaceutical industry lobby said.

Medicare AI Creates Errors and Delays for Patients, Doctors


Patients, doctors, and other healthcare professionals who spoke with KFF Health News say the effort has created confusion, errors, long wait times, and stress.

Is Creatine for Brain Health Worth a Try?


Research on creatine supplementation has moved from the gym to the brain lab, leading neurologist Heidi Moawad to review the data on creatine’s potential for improving cognitive health.

S1 Episode 2: Is Alcohol the Missing Piece in Your MASLD Workup?


Patients with MASLD often underreport alcohol use and even modest intake can block improvement. Drs VanWagner and Ajmera share practical tools to quantify intake, spot MetALD, and counsel patients effectively.

S1 Episode 1: Can Primary Care Catch MASLD Before Cirrhosis?


MASLD is a silent condition and labs may look normal. Drs VanWagner and Shubrook walk through who to screen, how to use FIB-4, and when primary care can manage MASLD without a specialist.

Palbociclib Gains HER2+ Breast Cancer Maintenance Indication


Palbociclib is now the first CDK4/6 inhibitor approved for metastatic disease regardless of HER2 status.

Mirvetuximab Fails to Boost Survival in Platinum-Eligible OC


Mirvetuximab has come up short in the first randomized trial testing an antibody-drug conjugate plus standard carboplatin for patients with platinum-sensitive ovarian cancer.

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

FDA Panel Endorses Capivasertib Use in Prostate Cancer

2.

Le cancer et le COVID ont conduit le patient à une double transplantation de poumon.

3.

Adaptive SABR-Used Hypofractionated Chemoradiation Showed Good Results in NSCLC.

4.

MRI-Guided TULSA Speeds Recovery vs Robotic Prostatectomy

5.

Low-Dose Radiation Provides Almost Perfect Control Over Slow-Growing Lymphoma.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot